Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
15 Mar 2021
15 Mar 2021
Historique:
received:
16
07
2020
accepted:
17
02
2021
entrez:
16
3
2021
pubmed:
17
3
2021
medline:
17
3
2021
Statut:
epublish
Résumé
T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival. Here, we hypothesize that adding acetylsalicylic acid (ASA) and low-dose interleukin (IL)-2 would increase the vaccine efficacy in a recurrent advanced OC phase I trial (NCT01132014). By adding ASA and low-dose IL-2 to the OCDC-Bev-Cy combinatorial regimen, we elicited vaccine-specific T-cell responses that positively correlated with patients' prolonged time-to-progression and overall survival. In the ID8 ovarian model, animals receiving the same regimen showed prolonged survival, increased tumor-infiltrating perforin-producing T cells, increased neoantigen-specific CD8
Identifiants
pubmed: 33723260
doi: 10.1038/s41541-021-00297-5
pii: 10.1038/s41541-021-00297-5
pmc: PMC7960755
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36Subventions
Organisme : NCI NIH HHS
ID : P50 CA083638
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
pubmed: 12529460
doi: 10.1056/NEJMoa020177
Santoiemma, P. P. et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol. Oncol. 143, 120–127 (2016).
pubmed: 27470997
doi: 10.1016/j.ygyno.2016.07.105
Leffers, N. et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 58, 449–459 (2008).
pubmed: 18791714
doi: 10.1007/s00262-008-0583-5
Tomšová, M., Melichar, B., Sedláková, I. & Šteiner, I. Prognostic significance of CD3
pubmed: 18037158
doi: 10.1016/j.ygyno.2007.10.016
Chiang, C. L.-L. et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin. Cancer Res. 19, 4801–4815 (2013).
pubmed: 23838316
pmcid: 4049094
doi: 10.1158/1078-0432.CCR-13-1185
Tanyi, J. L. et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci. Transl. Med. 10, 5931 (2018).
doi: 10.1126/scitranslmed.aao5931
Facciabene, A., Motz, G. T. & Coukos, G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162–2171 (2012).
pubmed: 22549946
pmcid: 3342842
doi: 10.1158/0008-5472.CAN-11-3687
Yamamoto, S. et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 76, 1221–1227 (1997).
pubmed: 9365173
pmcid: 2228134
doi: 10.1038/bjc.1997.537
Shen, G. H. et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 83, 196–203 (2000).
pubmed: 10901370
pmcid: 2363477
doi: 10.1054/bjoc.2000.1228
Kraft, A. et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85, 178–187 (1999).
pubmed: 9921991
doi: 10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7
Sato, E. et al. Intraepithelial CD8
pubmed: 16344461
pmcid: 1311741
doi: 10.1073/pnas.0509182102
Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004).
pubmed: 15322536
doi: 10.1038/nm1093
Randall, L. M. & Monk, B. J. Bevacizumab toxicities and their management in ovarian cancer. Gynecol. Oncol. 117, 497–504 (2010).
pubmed: 20363017
pmcid: 5109972
doi: 10.1016/j.ygyno.2010.02.021
Byrne, A. T. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9, 5721–5728 (2003).
pubmed: 14654557
Thun, M. J., Henley, S. J. & Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94, 252–266 (2002).
pubmed: 11854387
doi: 10.1093/jnci/94.4.252
Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591–1601 (2012).
pubmed: 22440947
doi: 10.1016/S0140-6736(12)60209-8
Ruder, E. H. et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am. J. Gastroenterol. 106, 1340–1350 (2011).
pubmed: 21407185
pmcid: 3183504
doi: 10.1038/ajg.2011.38
Sharpe, C. R. et al. Nested case–control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br. J. Cancer 83, 112–120 (2000).
pubmed: 10883678
pmcid: 2374529
doi: 10.1054/bjoc.2000.1119
Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607–615 (2014).
pubmed: 24793239
pmcid: 4060245
doi: 10.1038/nm.3541
Denkert, C. et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 160, 893–903 (2002).
pubmed: 11891188
pmcid: 1867167
doi: 10.1016/S0002-9440(10)64912-7
Liu, M. et al. Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Mod. Pathol. 22, 373–384 (2009).
pubmed: 18997734
doi: 10.1038/modpathol.2008.187
Rosenberg, S. A., Schwarz, S. & Spiess, P. J. In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. J. Immunol. 121, 1951–1955 (1978).
pubmed: 309485
doi: 10.4049/jimmunol.121.5.1951
Strausser, J. L. & Rosenberg, S. A. In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J. Immunol. 121, 1491–1495 (1978).
pubmed: 151716
doi: 10.4049/jimmunol.121.4.1491
Lotze, M. T., Grimm, E. A., Mazumder, A., Strausser, J. L. & Rosenberg, S. A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 41, 4420–4425 (1981).
pubmed: 6975652
Recchia, F. et al. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int. J. Oncol. 27, 1039–1046 (2005).
pubmed: 16142321
Khammari, A. et al. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Investig. Dermatol. 129, 2835–2842 (2009).
pubmed: 19554023
doi: 10.1038/jid.2009.144
Nguyen, L. T. et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol. Immunother. 68, 773–785 (2019).
pubmed: 30747243
doi: 10.1007/s00262-019-02307-x
Berntsen, A. et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J. Immunother 31, 771–780 (2008).
pubmed: 18779742
doi: 10.1097/CJI.0b013e3181833818
Trepiakas, R. et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 12, 721–734 (2010).
pubmed: 20429791
doi: 10.3109/14653241003774045
Ellebaek, E. et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol. Immunother. 61, 1791–1804 (2012).
pubmed: 22426890
doi: 10.1007/s00262-012-1242-4
Bobisse, S. et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8
pubmed: 29545564
pmcid: 5854609
doi: 10.1038/s41467-018-03301-0
Lutsiak, M. E. C. et al. Inhibition of CD4 + 25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862–2868 (2005).
pubmed: 15591121
doi: 10.1182/blood-2004-06-2410
Ghiringhelli, F. et al. CD4
pubmed: 14768038
doi: 10.1002/eji.200324181
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
pubmed: 15637262
doi: 10.1126/science.1104819
Wildiers, H. et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88, 1979–1986 (2003).
pubmed: 12799646
pmcid: 2741115
doi: 10.1038/sj.bjc.6601005
Hahnfeldt, P., Folkman, J. & Hlatky, L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol. 220, 545–554 (2003).
pubmed: 12623285
doi: 10.1006/jtbi.2003.3162
Gorbachev, A. V. et al. CXC Chemokine ligand 9/monokine induced by IFN-γ production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J. Immunol. 178, 2278–2286 (2007).
pubmed: 17277133
doi: 10.4049/jimmunol.178.4.2278
Pan, J. et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J. Immunol. 176, 1456–1464 (2006).
pubmed: 16424173
doi: 10.4049/jimmunol.176.3.1456
Watchmaker, P. B. et al. Independent regulation of chemokine responsiveness and cytolytic function versus CD8
pubmed: 20018619
doi: 10.4049/jimmunol.0902062
Kalinski, P. & Okada, H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol. 22, 173–182 (2010).
pubmed: 20409732
pmcid: 2892234
doi: 10.1016/j.smim.2010.03.002
McNeil, J. J. et al. Effect of aspirin on all-cause mortality in the healthy elderly. N. Engl. J. Med. 379, 1519–1528 (2018).
pubmed: 30221595
pmcid: 6433466
doi: 10.1056/NEJMoa1803955
Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209–217 (2019).
pubmed: 30472651
doi: 10.1136/annrheumdis-2018-214229
Ahmadzadeh, M. & Rosenberg, S. A. IL-2 administration increases CD4
pubmed: 16304057
pmcid: 1473973
doi: 10.1182/blood-2005-06-2399
Cesana, G. C. et al. Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169–1177 (2006).
pubmed: 16505437
doi: 10.1200/JCO.2005.03.6830
van der Vliet, H. J. et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13, 2100–2108 (2007).
pubmed: 17404092
doi: 10.1158/1078-0432.CCR-06-1662
Martin, S. D. et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS ONE 11, e0155189 (2016).
pubmed: 27192170
pmcid: 4871527
doi: 10.1371/journal.pone.0155189
Bassani-Sternberg, M. et al. A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma—a proof of antigen discovery feasibility in three patients. Front. Immunol. 10, 1832 (2019).
pubmed: 31440238
pmcid: 6694698
doi: 10.3389/fimmu.2019.01832
Bassani-Sternberg, M. et al. Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Comput. Biol. 13, e1005725 (2017).
pubmed: 28832583
pmcid: 5584980
doi: 10.1371/journal.pcbi.1005725
Gfeller, D. et al. The length distribution and multiple specificity of naturally presented HLA-I ligands. J. Immunol. 201, 3705–3716 (2018).
pubmed: 30429286
doi: 10.4049/jimmunol.1800914
Racle, J. et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nat. Biotechnol. 37, 1283–1286 (2019).
pubmed: 31611696
doi: 10.1038/s41587-019-0289-6
Lonsdale, J. et al. The genotype-tissue expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).
doi: 10.1038/ng.2653
Müller, M., Gfeller, D., Coukos, G. & Bassani-Sternberg, M. ‘Hotspots’ of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization. Front. Immunol. 8, 1367 (2017).
pubmed: 29104575
pmcid: 5654951
doi: 10.3389/fimmu.2017.01367
Roby, K. F. et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21, 585–591 (2000).
pubmed: 10753190
doi: 10.1093/carcin/21.4.585
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
pubmed: 26343581
pmcid: 4597191
doi: 10.1016/j.cell.2015.08.015
Garboczi, D. N., Hung, D. T. & Wiley, D. C. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl Acad. Sci. USA 89, 3429–3433 (1992).
pubmed: 1565634
pmcid: 48881
doi: 10.1073/pnas.89.8.3429
Zhang, W. et al. Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies. Lab. Investig. 97, 873–885 (2017).
pubmed: 28504684
doi: 10.1038/labinvest.2017.37
Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytom. A 79, 167–174 (2011).
doi: 10.1002/cyto.a.21015